Press Releases

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Press Releases

May 16, 2018

– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy – – Both doses significantly reduced drop seizure frequency in patients with poor seizure

Apr 19, 2018

LONDON and CARLSBAD, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW”, “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along

Apr 12, 2018

Long-Term Safety and Efficacy Data in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome to be Presented LONDON , April 12, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and

Mar 13, 2018
LONDON and CARLSBAD, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along

Ways to keep up to date with GW